



**FROM  
RESEARCH  
TO REALITY**

Global Summit on  
Psychedelic-Assisted  
Therapies and Medicine

**May 26-29, 2022— Hilton Toronto, ON**  
**Preliminary Program**

<b>Thursday, May 26</b>	
Time	Meeting Sequence
9:00 am – 12:00 pm	Two Optional half day workshops
1:00 pm – 4:00 pm	Two Optional half day workshops

<b>Session Legend</b>		
Neuroscience / clinical applications stream	Traditional medicine / cultural considerations stream	Public health, policy and regulatory directions stream

<b>Friday, May 27</b>							
<b>Theme: Prevention and Treatment of Substance Use Disorders: Progress and Prospects for Psychedelic Science</b>							
8:00 – 8:45	<b>Conference Opening</b> <ul style="list-style-type: none"> <li>Land acknowledgement by Clayton Shirt, Dalla Lana School of Public Health, University of Toronto</li> <li>Welcome from host (CAMH) and collaborating institutions (CCSA, MHCC)</li> </ul>						
8:45 – 9:45	<b>Plenary Presentation #1: <i>Historical and recent advances in psychedelic science, neuroscience and clinical contributions to substance use and addictions</i></b> <ul style="list-style-type: none"> <li>Dr David Nutt, Imperial College London</li> <li>Discussant: Dr Erica Dyck, University of Saskatchewan</li> <li>Discussant: Dr Doris Payer, Canadian Centre on Substance Use and Addiction</li> </ul>						
<b>9:45 – 10:15: Break</b>							
10:15 – 11:45	<b>Peer-Reviewed Paper presentations focused on neuroscience/clinical findings in substance use/addictions (5 of 15 minutes)</b>						
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%; text-align: center;">Abstract</th> <th style="width: 50%; text-align: center;">Authors</th> </tr> </thead> <tbody> <tr> <td style="vertical-align: top;">ID-25 <b>The impact of ineffective placebo control in microdosing trials</b></td> <td style="vertical-align: top;"> <ul style="list-style-type: none"> <li><u>Balazs Szigeti</u>, Imperial College London;<sup>1</sup></li> <li>Robin Carhart-Harris, University of California, San Francisco;</li> <li>David Erritzoe, Imperial College London</li> </ul> </td> </tr> <tr> <td style="vertical-align: top;">ID-8 <b>MDMA Therapy for the Treatment of Alcohol Use Disorder: The Results of the World’s First Study - And Plans for Ongoing Further Research.</b></td> <td style="vertical-align: top;"> <ul style="list-style-type: none"> <li><u>Ben Sessa</u>, Awakn Life Sciences</li> </ul> </td> </tr> </tbody> </table>	Abstract	Authors	ID-25 <b>The impact of ineffective placebo control in microdosing trials</b>	<ul style="list-style-type: none"> <li><u>Balazs Szigeti</u>, Imperial College London;<sup>1</sup></li> <li>Robin Carhart-Harris, University of California, San Francisco;</li> <li>David Erritzoe, Imperial College London</li> </ul>	ID-8 <b>MDMA Therapy for the Treatment of Alcohol Use Disorder: The Results of the World’s First Study - And Plans for Ongoing Further Research.</b>	<ul style="list-style-type: none"> <li><u>Ben Sessa</u>, Awakn Life Sciences</li> </ul>
Abstract	Authors						
ID-25 <b>The impact of ineffective placebo control in microdosing trials</b>	<ul style="list-style-type: none"> <li><u>Balazs Szigeti</u>, Imperial College London;<sup>1</sup></li> <li>Robin Carhart-Harris, University of California, San Francisco;</li> <li>David Erritzoe, Imperial College London</li> </ul>						
ID-8 <b>MDMA Therapy for the Treatment of Alcohol Use Disorder: The Results of the World’s First Study - And Plans for Ongoing Further Research.</b>	<ul style="list-style-type: none"> <li><u>Ben Sessa</u>, Awakn Life Sciences</li> </ul>						

<sup>1</sup> The presenting author is underlined.

Friday, May 27

**Theme: Prevention and Treatment of Substance Use Disorders: Progress and Prospects for Psychedelic Science**

ID-37	Safety of legal psilocybin use in Canada: a prospective, observational, study of patients authorized for psilocybin treatment	<ul style="list-style-type: none"> <li>• <a href="#">M. Ishrat Husain</a>, Centre for Addiction and Mental Health, Toronto;</li> <li>• Olga Chernoloz, Wake Network</li> </ul>
ID-11	Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice	<ul style="list-style-type: none"> <li>• <a href="#">Elizabeth Nielson</a>, Fluence</li> </ul>
ID-65	The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity	<ul style="list-style-type: none"> <li>• Peter Bedford, Centre for Addiction and Mental Health;</li> <li>• Daniel Hauke, University of Basel;</li> <li>• Zheng Wang, Centre for Addiction and Mental Health;</li> <li>• Volker Roth, University of Basel;</li> <li>• Monika Nagy-Huber, University of Basel;</li> <li>• Friederike Holze, University of Basel;</li> <li>• Laura Ley, Departement Biomedizin, University of Basel;</li> <li>• Patrick Vizeli, Departement Biomedizin, University of Basel;</li> <li>• Matthias Liechti, University of Basel;</li> <li>• Stefan Borgward, University of Basel t;</li> <li>• Felix Müller, University Psychiatric Clinics Basel;</li> <li>• <a href="#">Andreea Diaconescu</a>, Centre for Addiction and Mental Health</li> </ul>
<b>11:45 – 12:45: Lunch</b>		
12:45 – 1:45	<b>Plenary presentation #2: <i>Traditional medicine, culture and psychedelic science: Healing for substance use and addictions</i></b> <ul style="list-style-type: none"> <li>• Dr Anja Loizaga-Velder, National Autonomous University of Mexico</li> </ul>	
1:45 – 3:15	<b>Peer-Reviewed Paper Presentations focused on traditional approaches to substance use/addictions (5 of 15 minutes)</b>	
ID-47	Naturalistic Psychedelic use Among Indigenous Peoples to Alleviate Racial Trauma	<ul style="list-style-type: none"> <li>• <a href="#">Sara de la Salle</a>, University of Ottawa;</li> <li>• Sophia Gran-Ruaz, University of Ottawa;</li> <li>• Dawn Davis, NativeSci;</li> <li>• Monnica Williams, University of Ottawa;</li> <li>• Alan Davis, Ohio State University</li> </ul>
ID-22	Integrating Anthropological Knowledge into Psychedelic Spiritual Care: How Indigenous Wisdom and Ayahuasca Religions can inform Best Practice	<ul style="list-style-type: none"> <li>• <a href="#">Marc Blainey</a>, Homewood Health Centre</li> </ul>



**FROM  
RESEARCH  
TO REALITY**

Global Summit on  
Psychedelic-Assisted  
Therapies and Medicine

Friday, May 27

**Theme: Prevention and Treatment of Substance Use Disorders: Progress and Prospects for Psychedelic Science**

ID-114	Preliminary results from the Ayahuasca Treatment Outcome Project (ATOP): Takiwasi Center Peru.	<ul style="list-style-type: none"> <li>• <a href="#">Brian Rush</a>, Centre for Addiction and Mental Health</li> </ul>
ID-28	Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being	<ul style="list-style-type: none"> <li>• <a href="#">Maggie Kiraga</a>;</li> <li>• Natasha Mason, Maastricht University;</li> <li>• Malin Uthaug, Maastricht University;</li> <li>• Kim van Oorsouw, Maastricht University;</li> <li>• Stefan Toennes, University of Frankfurt;</li> <li>• Johannes Ramaekers, Maastricht University;</li> <li>• Kim Kuypers, Maastricht University</li> </ul>
<b>3:15 – 3:45: Break</b>		
3:45 – 5:15	<b>Peer-Reviewed Paper Presentations focused on policy, public health, and regulatory issues in substance use and addictions (5 of 15 minutes)</b>	
ID-46	Psychedelics for addiction treatment: enabling access and protecting innovation and opportunity through preserving the public domain	<ul style="list-style-type: none"> <li>• Shahin Shams, Usona Institute;</li> <li>• Sisi Li, Usona Institute;</li> <li>• Amanda Pratt, Holtz Center for Science and Technology Studies;</li> <li>• David Casimir, Casimir Jones S.C.;</li> <li>• Thomas Isenbarger, Casimir Jones S.C.</li> </ul>
ID-50	From Policy to Practice, Practice to Policy (P2P): An Interdisciplinary and Practice Based Approach to Ketamine Assisted Therapy Policy Development in Canada	<ul style="list-style-type: none"> <li>• Anthony Barale, The Ketamine Assisted Therapy Association of Canada;</li> <li>• Ian Mitchell, Royal Inland Hospital;</li> <li>• Joel Kailia, The Ketamine Assisted Therapy Association of Canada;</li> <li>• <a href="#">Madison Nobbs</a>, Ketamine Assisted Therapy Association of Canada;</li> <li>• Neil Hanon, Ketamine Assisted Therapy Association of Canada;</li> <li>• Sukh Dhiman, The Ketamine Assisted Therapy Association of Canada</li> </ul>
ID-118	The future of psychedelic therapies in health system stewardship	<ul style="list-style-type: none"> <li>• <a href="#">Kenneth Tupper</a>, University of British Columbia</li> </ul>
ID-5	The Canadian Psychedelic Survey; A Cross-Sectional Survey of Psychedelic Use in Canada	<ul style="list-style-type: none"> <li>• <a href="#">Philippe Lucas</a>, Sabi Mind</li> </ul>

<b>Friday, May 27</b> <b>Theme: Prevention and Treatment of Substance Use Disorders: Progress and Prospects for Psychedelic Science</b>	
<b>5:30 – 6:30</b>	Evening Panel: <i>Policy, public health, and regulatory issues: Setting the research agenda for psychedelic-assisted therapies for substance use disorders</i>  What are the steps for developing new treatment pathways for substance use disorders with psychedelic-assisted therapies including key research questions, regulatory issues, risk assessment, potential concerns or benefits, etc. <ul style="list-style-type: none"> <li>Ken Tupper, University of British Columbia</li> <li>Ifetayo Harvey, POC Psychedelic Collective</li> <li>Representative from Health Canada</li> <li>Representative from the Food and Drug Administration</li> <li>Moderator: Dr Dominique Morisano</li> </ul>
<b>8:00 – 9:30</b>	<b>Networking Social Event</b>

<b>Saturday, May 28</b> <b>Theme: Prevention and Treatment of Mental Health Disorders: Part I: Neuroscience/ Clinical Applications; Traditional Medicine/Cultural Considerations</b>													
<b>8:15 – 8:30</b>	<b>Opening Remarks</b>												
<b>8:30 – 9:30</b>	<b>Plenary Presentation #3: <i>Psychedelics and Racial Justice</i></b> <ul style="list-style-type: none"> <li>Dr Monnica Williams, School of Psychology, University of Ottawa</li> </ul>												
<b>9:30 – 10:15</b>	<b>Poster viewing and break</b>												
<b>10:15 – 11:45</b>	<b>Peer-Reviewed Paper presentations focused on neuroscience/clinical findings (5 of 15 minutes)</b>												
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 35%; text-align: center;">Abstract</th> <th style="width: 35%; text-align: center;">Authors</th> </tr> </thead> <tbody> <tr> <td style="vertical-align: top;">ID-17</td> <td style="vertical-align: top;">Safety, efficacy, durability and feasibility of MDMA-assisted therapy for the treatment of PTSD</td> <td style="vertical-align: top;"> <ul style="list-style-type: none"> <li>Jennifer Mitchell, UCSF;</li> <li>Charlotte Harrison, MAPS;</li> <li>Alia Lilienstein, MAPS;</li> <li>Elliot Marseille, UC Berkeley;</li> <li>Allison Coker, MAPS Public Benefit Corporation;</li> <li>Berra Yazar-Klosinski, MAPS</li> </ul> </td> </tr> <tr> <td style="vertical-align: top;">ID-78</td> <td style="vertical-align: top;">The Effects of Psilocybin on Cognitive and Neural Flexibility: The Limits of Excessive Flexing</td> <td style="vertical-align: top;"> <ul style="list-style-type: none"> <li>Manoj Doss, Johns Hopkins University School of Medicine</li> </ul> </td> </tr> <tr> <td style="vertical-align: top;">ID-93</td> <td style="vertical-align: top;">Psychedelic microdosers report therapeutic motivations and longitudinal improvements in mood, mental health and psychomotor functioning relative to non-microdosing comparators</td> <td style="vertical-align: top;"> <ul style="list-style-type: none"> <li>Joseph Rootman, UBC Okanagan;</li> <li>Pamela Kryskow, Vancouver Island University;</li> <li>Maggie Kiraga;</li> <li>Paul Stamets;</li> <li>Kalin Harvey, Quantified Citizen;</li> <li>Eesmyal Santos-Brault, Quantified Citizen;</li> </ul> </td> </tr> </tbody> </table>		Abstract	Authors	ID-17	Safety, efficacy, durability and feasibility of MDMA-assisted therapy for the treatment of PTSD	<ul style="list-style-type: none"> <li>Jennifer Mitchell, UCSF;</li> <li>Charlotte Harrison, MAPS;</li> <li>Alia Lilienstein, MAPS;</li> <li>Elliot Marseille, UC Berkeley;</li> <li>Allison Coker, MAPS Public Benefit Corporation;</li> <li>Berra Yazar-Klosinski, MAPS</li> </ul>	ID-78	The Effects of Psilocybin on Cognitive and Neural Flexibility: The Limits of Excessive Flexing	<ul style="list-style-type: none"> <li>Manoj Doss, Johns Hopkins University School of Medicine</li> </ul>	ID-93	Psychedelic microdosers report therapeutic motivations and longitudinal improvements in mood, mental health and psychomotor functioning relative to non-microdosing comparators	<ul style="list-style-type: none"> <li>Joseph Rootman, UBC Okanagan;</li> <li>Pamela Kryskow, Vancouver Island University;</li> <li>Maggie Kiraga;</li> <li>Paul Stamets;</li> <li>Kalin Harvey, Quantified Citizen;</li> <li>Eesmyal Santos-Brault, Quantified Citizen;</li> </ul>
	Abstract	Authors											
ID-17	Safety, efficacy, durability and feasibility of MDMA-assisted therapy for the treatment of PTSD	<ul style="list-style-type: none"> <li>Jennifer Mitchell, UCSF;</li> <li>Charlotte Harrison, MAPS;</li> <li>Alia Lilienstein, MAPS;</li> <li>Elliot Marseille, UC Berkeley;</li> <li>Allison Coker, MAPS Public Benefit Corporation;</li> <li>Berra Yazar-Klosinski, MAPS</li> </ul>											
ID-78	The Effects of Psilocybin on Cognitive and Neural Flexibility: The Limits of Excessive Flexing	<ul style="list-style-type: none"> <li>Manoj Doss, Johns Hopkins University School of Medicine</li> </ul>											
ID-93	Psychedelic microdosers report therapeutic motivations and longitudinal improvements in mood, mental health and psychomotor functioning relative to non-microdosing comparators	<ul style="list-style-type: none"> <li>Joseph Rootman, UBC Okanagan;</li> <li>Pamela Kryskow, Vancouver Island University;</li> <li>Maggie Kiraga;</li> <li>Paul Stamets;</li> <li>Kalin Harvey, Quantified Citizen;</li> <li>Eesmyal Santos-Brault, Quantified Citizen;</li> </ul>											

<p style="text-align: center;"><b>Saturday, May 28</b></p> <p style="text-align: center;"><b>Theme: Prevention and Treatment of Mental Health Disorders: Part I: Neuroscience/ Clinical Applications; Traditional Medicine/Cultural Considerations</b></p>		
		<ul style="list-style-type: none"> <li>• Kim Kuypers, Maastricht University;</li> <li>• Zach Walsh, University of British Columbia – Okanagan</li> </ul>
ID-106	Five Elements of Optimal Psychedelic Experience	<ul style="list-style-type: none"> <li>• <a href="#">Raquel Bennett</a>, KRIYA Institute</li> </ul>
ID-75	Trial of Psilocybin versus Escitalopram for Depression; 6 months follow-up data	<ul style="list-style-type: none"> <li>• <a href="#">David Erritzoe</a>, Imperial College London;</li> <li>• Rosalind Watts, Twelve Trees Integration Ltd;</li> <li>• Bruna Giribaldi, Imperial College London;</li> <li>• Balazs Szigeti, Imperial College London;</li> <li>• Fernando Rosas, Imperial College London;</li> <li>• David Nutt, Imperial College London;</li> <li>• Robin Carhart-Harris, University of California, San Francisco</li> </ul>
<b>11:45 – 12:45: Lunch</b>		
12:45 – 2:15	<b>Peer-Reviewed Paper Presentations focused on traditional approaches (5 of 15 minutes)</b>	
ID-51	Revolution or an endless cycle? The epistemic and ethical concerns of psychedelic psychiatry	<ul style="list-style-type: none"> <li>• <a href="#">Olivia Marcus</a>, New York University</li> </ul>
ID-63	Psychedelic Medicine and Muslim Communities: From Sufism to the Modern Era	<ul style="list-style-type: none"> <li>• <a href="#">Manzarsadat Zareashkezari</a>, University of Ottawa</li> </ul>
ID-29	Exploring experiences and perceptions around purging during Ayahuasca rituals: a qualitative study at a drug rehabilitation center in Peru	<ul style="list-style-type: none"> <li>• <a href="#">Svět Lustig Vijay</a>, London School of Tropical Hygiene and Medicine;</li> <li>• Fabio Friso, Center for the Rehabilitation of Drug Addicts and Research on Traditional Medicines;</li> <li>• Magdalena Harris, Department of Public Health, Environments and Society, London School of Tropical Hygiene and Medicine;</li> <li>• Matteo Politi, Center for the Rehabilitation of Drug Addicts and Research on Traditional Medicines</li> </ul>
ID-96	Culturally-Safe Psychedelic-Assisted Psychotherapy: A Foundation for Training Programs	<ul style="list-style-type: none"> <li>• <a href="#">Tatiana Sanchez</a>, University of British Columbia - Okanagan;</li> <li>• Sarah Daniels, University of British Columbia - Okanagan;</li> <li>• Michelle St. Pierre, The University of British Columbia;</li> <li>• Joseph Rootman, UBC Okanagan;</li> <li>• Christopher Nelson, University of British Columbia - Okanagan;</li> <li>• Zach Walsh, University of British Columbia –</li> </ul>

Saturday, May 28	
Theme: Prevention and Treatment of Mental Health Disorders: Part I: Neuroscience/ Clinical Applications; Traditional Medicine/Cultural Considerations	
	Okanagan
2:15 – 3:45	Plenary presentation #4: <i>Spirit in Science—Traditional and Indigenous Perspectives on Healing Trauma with Psychedelic Plant Medicines</i> <ul style="list-style-type: none"> <li>• Dr Joseph Tafur, Ocotillo Center for Integrative Medicine</li> <li>• Chief Derek Cook, Bloodvein First Nation</li> </ul>
<b>3:45 – 4:15: Break</b>	
4:15 – 5:45	Late Breaking Research Presentations (all topics) (15 of 5 minutes)
7:30 – 9:00	Public Event with Speaker

Sunday, May 29	
Theme: Prevention and Treatment of Mental Health Disorders: Part II: Public Health, Policy, and Regulatory Considerations	
8:00 – 8:30	Opening Remarks
8:30 – 9:30	Plenary Presentation #5
9:30 – 10:15	Poster viewing and break
10:15 – 11:45	Peer-Reviewed Paper presentations focused on policy, public health, and regulatory issues (5 of 15 minutes)
	<b>Abstract</b>
	<b>Authors</b>
ID-98:	<p><b>The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of its Provision</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Sonya Faber</a>, Bioville GmbH; Darron Smith, The University of Memphis</li> </ul>
ID-100:	<p><b>Entheogens and Psychedelics in Canada, Proposal for a New Paradigm: A Call for a National Advisory Council</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Jessica Rochester</a>, Céu do Montreal;</li> <li>• Anne Vallély, University of Ottawa;</li> <li>• Monnica Williams, University of Ottawa;</li> <li>• Paul Grof, Mood Disorders Centre of Ottawa;</li> <li>• Kate Caldwell, Interaction Experience;</li> <li>• Harvey Chang, Jewish General Hospital</li> </ul>
ID-58:	<p><b>Psychedelics and the Commercial Determinants of Health: An Ethics Case Study Analysis of Psychedelic Industry-Healthcare Relationships</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Daniel Buchman</a>, Centre for Addiction and Mental Health</li> </ul>
ID-76:	<p><b>A grounded theory of online community members' self-reported decision-making logic before their first use of psychedelic self-treatment for depression and/or</b></p> <ul style="list-style-type: none"> <li>• <a href="#">David Kryszajtys</a>, University of Toronto;</li> <li>• Jacqueline Bender, University Health Network;</li> <li>• Brian Rush, Centre for Addiction and Mental Health;</li> </ul>

Sunday, May 29		
Theme: Prevention and Treatment of Mental Health Disorders: Part II: Public Health, Policy, and Regulatory Considerations		
	anxiety.	<ul style="list-style-type: none"> <li>Carol Strike, University of Toronto</li> </ul>
ID-23:	From Research to Regulatory Negotiations to Reality	<ul style="list-style-type: none"> <li><a href="#">Rick Doblin</a>, MAPS</li> </ul>
<b>11:45 – 12:45: Lunch</b>		
12:45 – 2:15	<b>World Regulatory and Policy Discussion: A Pathway Forward</b> <ul style="list-style-type: none"> <li>Representative from the World Health Organization</li> <li>Representative from the European Medicines Agency</li> <li>Representative from the Food and Drug Administration (FDA) (USA)</li> <li>Representative from the National Commission Against Addictions (CONADIC) (Mexico)</li> <li>Moderator: Dr. Doris Payer, Canadian Centre on Substance Use and Addiction</li> </ul>	
2:15 – 3:15	<b>Closing Plenary: <i>Psychedelics in mental health and addiction treatment</i></b> <ul style="list-style-type: none"> <li>Dr Matthew Johnson, Center for Psychedelic and Consciousness Research, Johns Hopkins University</li> </ul>	
3:15 – 3:45	<b>Closing Ceremony</b>	

**NOTE: Program subject to change at the sole discretion of the Conference Planning Committee**